Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

15Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Anti-PD-1 and BRAF-inhibitors (BRAFi) have been approved as first-line treatments in advanced melanoma. To date, no prospective data are available to give the best sequence of treatment. The objective of this study was to evaluate in real-life the efficacy of anti-PD-1 after BRAFi, ipilimumab, or chemotherapy failure. Methods: This was a single institution cohort analysis in patients treated with anti-PD-1 right after BRAFi, ipilimumab, or chemotherapy failure. Melanoma evolution after anti-PD-1 initiation was analyzed in BRAF-mutated and BRAF wild-type patients. The efficacy of treatment was evaluated by Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS), and Overall Survival (OS). Results: Seventy-four patients were included: 33 wild-type and 41 BRAF-mutated melanoma. ORR to anti-PD-1 was significantly lower in BRAF-mutated patients (12.2% vs. 45.5%, p=0.002). After anti-PD-1 initiation, the median PFS and OS was significantly shorter in the BRAF mutated group (2 vs. 5months and 7 vs. 20months, p=0.001). The hazard ratio for disease progression was of 2.3 (95%CI:1.3-3.9; p=0.003) and 2.5 (95%CI:1.3-4.5; p=0.005) for death. Thirty-nine percent of BRAF-mutated-patients died within 3months after anti-PD-1 initiation. Rapid death (≤3months) was significantly higher in BRAF-mutated patients (55.2% vs. 20.0%, p=0.014). Discussion: This is the largest series of unselected patients treated in real-life with anti-PD-1 as second-or-higher line of treatment. Anti-PD-1 was less effective in BRAF-mutated cases as a majority of patients presented aggressive tumor evolution after BRAFi discontinuation. These data are consistent with previous studies suggesting a negative impact of BRAFi prior to immunotherapy.

Cite

CITATION STYLE

APA

Amini-Adle, M., Khanafer, N., Le-Bouar, M., Duru, G., Dalle, S., & Thomas, L. (2018). Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-018-4618-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free